Mol Cancer: Novel biomarker SNORD33 predicts sensitivity to platinum-based chemotherapy in triple-negative breast cancer

Triple-negative breast cancer is a subtype of breast cancer with high invasiveness and metastasis, high recurrence rate and low overall survival rate, which is a difficult clinical treatment
.

SnoRNAs are a class of small non-coding RNAs that participate in the biosynthesis of ribosomes and the splicing and assembly of spliceosomes.
They are abundant in plasma and can be used as potential biomarkers for liquid biopsy
.

Studies have found that SNORD33 can block the binding of the methylation-binding protein MeCP2 to its target genes, thereby releasing the transcriptional inhibitory activity of MeCP2, promoting the expression of apoptosis-related genes, and increasing the sensitivity of triple-negative breast cancer cells to platinum
.

The results of this study provide novel molecular markers and specific targets for therapy with high accuracy, convenient detection, and non-invasiveness
.

Article information and links: Biyun Wang ^1# , Yannan Zhao ^1,2# , Yi Li ^1,2# , Yingying Xu ^2# , Yun Chen ³ , Qiuyu Jiang ^2,4 , Dingjin Yao ² , Li Zhang ² , Xichun Hu1* , Chaowei Fu ^3* , Si Zhang ^2* , She Chen ^2* .
A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients.

https://molecular-cancer.
biomedcentral.
com/articles/10.
1186/s12943-022-01504-0

 Authors and fund support: Prof.
Wang Biyun, Physician Zhao Yannan, Physician Li Yi, Associate Prof.
Xu Yingying are the co-first authors, Prof.
Chen Tong, Prof.
Zhang Si, Prof.
Fu Zhaowei, and Prof.
Hu Xichun are the co-corresponding authors
.